Compare MOH & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MOH | GKOS |
|---|---|---|
| Founded | 1980 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.5B | 10.6B |
| IPO Year | 2002 | 2015 |
| Metric | MOH | GKOS |
|---|---|---|
| Price | $197.37 | $160.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 12 |
| Target Price | ★ $167.00 | $126.92 |
| AVG Volume (30 Days) | 437.6K | ★ 567.1K |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.46 | N/A |
| Revenue | ★ $45,426,000,000.00 | $507,442,000.00 |
| Revenue This Year | $2.40 | $23.32 |
| Revenue Next Year | $5.18 | $27.43 |
| P/E Ratio | $137.99 | ★ N/A |
| Revenue Growth | 11.75 | ★ 32.33 |
| 52 Week Low | $121.06 | $73.16 |
| 52 Week High | $244.89 | $191.62 |
| Indicator | MOH | GKOS |
|---|---|---|
| Relative Strength Index (RSI) | 45.24 | 36.95 |
| Support Level | $196.50 | $145.78 |
| Resistance Level | $204.11 | $161.53 |
| Average True Range (ATR) | 6.39 | 6.75 |
| MACD | 0.08 | -2.59 |
| Stochastic Oscillator | 35.10 | 8.62 |
Molina Healthcare Inc provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. The company operates in four reportable segments consisting of: 1) Medicaid; 2) Medicare; 3) Marketplace; and 4) Other. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in four states-California, New York, Texas, and Washington-account for over half of its enrollees.
Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. The company has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.